ABUS vs ARDX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ABUS · Arbutus Biopharma$3.66 ▼ 0.41%
ARDX · Ardelyx$2.88 ▼ 3.68%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ABUS -20.3%
- ARDX -49.0%
Head to head
| Metric | ABUS | ARDX |
|---|---|---|
| Price | $3.66 | $2.88 |
| Change today | ▼ 0.41% | ▼ 3.68% |
| Market cap | $724.08M | $723.95M |
| Return, 3 months | -20.4% | -28.0% |
| Return, year to date | -24.0% | -50.6% |
| Return, 1 year | -18.8% | -48.5% |
| P/E (TTM) | 4.6 | – |
| P/B | 2.8 | 4.4 |
| P/E percentile vs own 5y | 93rd | 65th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -90.6% | +23.8% |
| Net profit growth (YoY) | -303.8% | +12.4% |
| Gross margin | – | 94.4% |
| Operating margin | 81.1% | -7.9% |
| Net margin | 84.2% | -12.4% |
| Return on equity | 89.6% | -38.6% |
| Analyst target vs. price | – | +366.3% |
| Analyst buy share | – | 100% |
| RSI (14) | 29 | 37 |
| 30-day volatility | 49.8% | 50.9% |
| Max drawdown, 1 year | -29.9% | -64.0% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ABUS is the largest of the group by market value.
- ABUS has returned the most over the past year.
- ARDX is growing revenue fastest.
- ABUS keeps the most profit per dollar of sales.
- ABUS has been the calmest stock over the last 30 days.